Meloxicam sits in the middle of the pain relief spectrum. It’s effective for chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis, but several NSAIDs and other drug classes can deliver more intense pain relief, particularly for acute or severe pain. The trade-off is almost always more side effects, especially stomach and cardiovascular problems.
How Meloxicam Compares to Other NSAIDs
Meloxicam at its maximum daily dose of 15 mg performs roughly on par with diclofenac 100 mg for osteoarthritis pain. In a double-blind trial comparing the two, meloxicam actually showed a slight trend toward better pain reduction on movement and lower need for additional painkillers, though the difference wasn’t statistically significant. Where the two clearly diverged was side effects: 26% of diclofenac users experienced gastrointestinal problems compared to 16% on meloxicam.
Ketorolac is often considered one of the strongest oral NSAIDs available. In a study of acute dental pain, ketorolac 10 mg achieved a 64% success rate for pain control compared to 52% for meloxicam 7.5 mg (half the max dose). That said, ketorolac is only approved for short-term use, typically five days or fewer, because it carries a high risk of stomach bleeding and kidney damage with prolonged use. It’s the NSAID most commonly used as a substitute for opioids in emergency and post-surgical settings.
Indomethacin is another potent option. It inhibits both major inflammatory pathways aggressively, with a COX-2 to COX-1 ratio of 1.78, meaning it hits both pathways nearly equally. For comparison, meloxicam’s ratio is 0.09, making it far more selective toward the inflammatory pathway and much gentler on the stomach lining. Indomethacin is particularly effective for gout flares and certain types of severe headaches, but its broad mechanism makes GI side effects and headaches common.
Why Meloxicam Is Gentler Than Most NSAIDs
Your body produces two versions of an enzyme called cyclooxygenase. One version (COX-1) protects your stomach lining and supports kidney function. The other (COX-2) drives inflammation and pain. Most traditional NSAIDs block both, which is why they relieve pain but also cause stomach problems.
Meloxicam preferentially targets COX-2, sparing most of the stomach-protective COX-1 activity. Its selectivity ratio of 0.09 puts it in similar territory to celecoxib (0.11), a drug specifically designed as a COX-2 selective inhibitor. This selectivity is the main reason meloxicam causes fewer GI complications than drugs like diclofenac or indomethacin. It’s also why “stronger” NSAIDs aren’t automatically better. More pain relief typically comes with more risk to your stomach, kidneys, and cardiovascular system.
Topical NSAIDs: Equal Relief, Fewer Stomach Problems
If meloxicam isn’t controlling your pain well enough, switching to a stronger oral NSAID isn’t the only option. A meta-analysis of eight randomized trials involving over 2,000 osteoarthritis patients found that topical NSAIDs (like diclofenac gel) matched oral NSAIDs for both pain reduction and physical function improvement, with no statistically significant difference between the two on standard pain scales.
The advantage of going topical is the side effect profile. Gastrointestinal reactions were significantly more common with oral NSAIDs, while topical versions caused about five times more skin reactions (irritation, redness at the application site). For joint pain in areas close to the skin surface, like knees and hands, a topical NSAID can deliver the same relief as an oral one while keeping the drug mostly out of your bloodstream.
Prescription Alternatives Beyond NSAIDs
When people ask what’s “stronger” than meloxicam, they sometimes mean a different class of drug entirely. The answer depends on the type of pain.
Tramadol is a weak opioid often prescribed when NSAIDs aren’t enough. Interestingly, it doesn’t always outperform meloxicam. In a surgical pain study, patients given 15 mg of meloxicam actually reported less pain and used fewer additional painkillers than those given 50 mg of tramadol. Tramadol also carries risks of dependence, dizziness, and nausea that NSAIDs don’t have. It’s not a guaranteed step up in relief.
Stronger opioids like oxycodone or hydrocodone do provide more raw pain suppression than meloxicam, but they work through an entirely different mechanism (blocking pain signals in the brain rather than reducing inflammation at the source). For inflammatory conditions like arthritis, opioids treat the symptom without addressing the underlying process, and they come with well-known risks of tolerance and dependence.
Corticosteroid injections offer powerful localized anti-inflammatory effects for joint pain. A single injection into an arthritic knee can provide weeks to months of relief that meloxicam can’t match, though the effect is temporary and repeated injections carry their own risks to cartilage over time.
The Strength vs. Safety Trade-Off
A large systematic review of population-based studies found that cardiovascular risk increases across nearly all NSAIDs, with relative risk estimates generally ranging from 1.0 to 2.0 compared to non-users. Among less commonly studied NSAIDs, etoricoxib and indomethacin carried the highest cardiovascular risks. Meloxicam’s cardiovascular risk was about 10% higher than naproxen’s and appeared similar to ibuprofen and celecoxib.
For gastrointestinal complications, the picture is starker. The average relative risk of serious GI events across NSAIDs was around 4 times higher than in non-users. Meloxicam and celecoxib sit at the lower end of that range due to their COX-2 selectivity, while drugs like indomethacin and ketorolac sit at the higher end.
This is the core tension: the NSAIDs that hit harder also tend to cause more damage to the stomach and cardiovascular system. If meloxicam at 15 mg daily isn’t providing enough relief, the most productive conversation with a prescriber isn’t just “what’s stronger?” but “what’s the safest way to get more relief for my specific type of pain?” The answer might be adding a topical NSAID, trying a short course of a more potent NSAID like ketorolac, switching drug classes, or using a targeted injection rather than escalating oral medications.